Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2019-07-09 Capital/Financing Update
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated July 9, 2019, announcing a financing operation. Key phrases include 'ÉMISSION D'«OCA» POUR UN MONTANT NOMINAL MAXIMUM DE 15 M€' (Issuance of 'OCA' for a maximum nominal amount of 15 M€) and detailed descriptions of the terms of convertible bonds (OCA - Obligations Convertibles en Actions). This clearly relates to the company raising capital or changing its financing structure. This aligns directly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing agreement itself.
2019-07-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document text is a press release from DEINOVE announcing scientific data regarding their compound DNV3681, which was presented at the ASM Microbe 2019 congress by a representative from USAMRIID. It details research findings, mentions next steps (in vivo assessment), and includes boilerplate information about the involved entities (DEINOVE and USAMRIID). This format—a formal announcement of recent developments, research results, or corporate news that is not a mandated regulatory filing like a 10-K or a formal earnings report—is characteristic of a general corporate announcement or press release. Since there is no specific category for a scientific/research update press release, and it is not a formal financial report (like ER or IR), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements not covered elsewhere. The document length (6893 chars) is substantial enough that it is the report/announcement itself, not just a notice to publish a report (RPA).
2019-06-25 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from DEINOVE announcing the presentation of data regarding their compound DNV3681 at the ASM Microbe 2019 congress. It details scientific findings, mentions future *in vivo* assessments by USAMRIID, and includes quotes from the Scientific Director. This format—a formal announcement of scientific or business progress, often summarizing external presentations or studies—is characteristic of a general press release or regulatory update that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a formal announcement of company activity and scientific progress, and it is not a transcript (CT), a formal financial report (10-K, IR), or a specific corporate action notice (DIV, CAP, DIRS), the most appropriate general category for a non-standard regulatory announcement is 'Regulatory Filings' (RNS), which serves as a broad category for official company disclosures that don't fit elsewhere.
2019-06-24 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 24, 2019, from the French biotechnology company DEINOVE. It announces scientific data regarding their compound DNV3681 presented at the ASM Microbe 2019 conference by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The text details efficacy results against bioterrorism threat pathogens and includes quotes from the Scientific Director and background information on both DEINOVE and USAMRIID. This format—a formal announcement of recent news, scientific findings, or business developments, often including contact information and boilerplate company descriptions—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific shareholder/management action document, and it serves to disseminate timely, material information to the market, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS). Given the content is a scientific update rather than a summary of quarterly financial performance, RNS is a strong candidate, but ERs often include non-financial operational highlights. However, looking at the definitions, this is a specific announcement of research results, which often falls under general regulatory disclosure. Since it is not a formal financial report summary (ER) but a specific operational/scientific update, and it doesn't fit other specific categories (like M&A, Capital, Management Change), the most appropriate general category for timely, non-standard disclosures is Regulatory Filings (RNS). If the document were a summary of quarterly results, ER would be chosen. Since it is a scientific press release, RNS is the best fit as a catch-all for important, non-standard disclosures.
2019-06-24 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 11, 2019, announcing the progress of a collaborative program between DEINOVE and AVRIL regarding the development of a natural ingredient for animal feed. It details scientific validation, regulatory steps being initiated, and future commercialization goals. This type of announcement, focusing on business development, partnerships, and progress toward a product launch, is characteristic of a general corporate update or press release. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (like AR or IR), and it is not explicitly announcing the publication of a major report (which would suggest RPA), the most appropriate classification is Regulatory Filings (RNS) as a general corporate communication that doesn't fit the highly specific categories, or potentially a Capital/Financing Update (CAP) if the development was tied to specific funding, but here it seems more like a progress update. Given the nature of the announcement (progress update on a collaboration), and lacking specific regulatory form headers, RNS serves as the best general category for non-standard corporate news releases.
2019-06-11 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is a press release announcing the progress of a collaborative program between DEINOVE and Avril regarding the development of a natural feed additive. It details testing results, regulatory steps being initiated, and future commercialization plans. This type of announcement, focusing on operational progress, partnerships, and product development milestones, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER) or corporate governance filings (like DEF 14A, DVA). Since it is a general corporate update that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it is best classified as a general Regulatory Filing or Announcement, which corresponds to RNS, the fallback category for miscellaneous regulatory announcements.
2019-06-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.